更新于：2024-11-01

Shanghai Xuhui District Central Hospital

中国上海市

更新于：2024-11-01

概览

概览

关联

项与 Shanghai Xuhui District Central Hospital 相关的临床试验

NCT06451783 / Enrolling by invitation早期临床1期IIT

The Clinical Efficacy of Shengyu Decoction Combined With Lijin Manipulation in the Treatment of Knee Osteoarthritis Was Observed Based on Three-dimensional Gait Analysis System

Detailed Description Avoid duplicating information that will be entered or uploaded elsewhere in the record.

开始日期2024-05-01

申办/合作机构

Shanghai Xuhui District Central Hospital

NCT06329999 / RecruitingN/AIIT

A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML

The goal of this clinical trial] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia]. The main questions it aims to answer are:
Evaluation of the efficacy
Evaluation of the safety

开始日期2024-02-03

申办/合作机构

复旦大学附属中山医院

[+11]

NCT05818735 / RecruitingN/AIIT

Efficacy and Safety of Electroacupuncture on Treating the First Episode of Mild to Moderate Depression

Depression is a disease that endangers the physical and mental health of all human beings. Only 30-40% of patients with initial episode depression are cured after treatment with antidepressants. Acupuncture is a widely recognized therapy to treat depression in clinical practice, and it can effectively relieve the depressive mood and improve related physical symtoms in patients with mild to moderate depression. This randomised controlled trial (RCT) is aimed to investigate the efficacy and safety of electroacupuncture (EA) in the treatment for patients with the first-episode of mild to moderate depression.

开始日期2023-12-01

申办/合作机构

上海市精神卫生中心（上海市心理咨询培训中心）

[+1]

100 项与 Shanghai Xuhui District Central Hospital 相关的临床结果

登录后查看更多信息

0 项与 Shanghai Xuhui District Central Hospital 相关的专利（医药）

登录后查看更多信息

项与 Shanghai Xuhui District Central Hospital 相关的文献（医药）

2024-03-01·Clinical Rheumatology

Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study

Article

作者: Yang, Jianmei ; Lv, Shun ; Qiao, Liang ; Meng, Kai

OBJECTIVETo evaluate the potential impact of consistent use of similar treatments over a long period; it is essential to investigate the potential correlation between genetic variations that influence the expression or function of pharmacological targets for reducing lipid levels and the risk of developing rheumatoid arthritis.METHODSWe used variants in the following genes to conduct Mendelian randomization analyses: HMGCR (encoding the target for statins), PCSK9 (encoding the target for PCSK9 inhibitors, such as evolocumab and alirocumab), and NPC1L1 (encoding the target for ezetimibe). Data from lipid genetics consortia (173,082 sample size) were used to weight variations according to their correlations with low-density lipoprotein cholesterol (LDL-C). In two large datasets (total n = 19,562 cases, 501,655 controls). We conducted a meta-analysis of Mendelian randomization estimates, weighted by LDL-C levels, on the regional differences in the risk of rheumatoid arthritis using data from two large databases.RESULTSWe approached SMR and IVW-MR analyses to examine the relationship between target gene expression (including HMGCR, PCSK9, and NPC1L1) and LDL-C levels mediated by these genes with RA. The IVW-MR analysis revealed no significant association between genetically predicted LDL-C concentration and the risk of RA (OR = 0.88, 95% CI = 0.59-1.29; OR = 0.91, 95% CI = 0.67-1.23; OR = 0.81, 95% CI = 0.49-1.36; all p > 0.05). Similarly, our findings from the SMR approach provided no evidence to suggest that gene expression of HMGCR, PCSK9, and NPC1L1 was associated with the risk of RA (OR = 0.91, 95% CI = 0.79-1.05, p = 0.207; OR = 0.96, 95% CI = 0.85-1.09, p = 0.493).CONCLUSIONSOur results do not provide evidence to support the hypothesis that reducing LDL-C levels with statins, alirocumab, or ezetimibe effectively prevents the risk of developing RA. However, our study provides valuable insights into the assessment of lipid-lowering agents in RA, which can enhance our understanding of the condition and assist in clinical practice by aiding in the determination and monitoring of RA status to clinical response.

2024-03-01·The Innovation

GTF2H4 regulates partial EndMT via NF-κB activation through NCOA3 phosphorylation in ischemic diseases

Article

作者: Qin, Shengying ; Zhang, Zhentao ; Li, Haomin ; Hong, Hangnan ; Ge, Junbo ; Huang, Dong ; Huang, Lei ; Feng, Runyang ; Zhao, Xin ; Zhong, Xin ; Chen, Zhaoyang ; Yu, Xueting ; Zhu, Jinhang ; Wang, Xiangdong ; Li, Peng ; Lu, Hao ; Zheng, Hongchao ; Zhang, You-En ; Zhao, Gang ; Abdurahman, Mukaddas ; Guo, Junjie ; He, Yue ; Fang, Zheyan ; Zhang, Wenbin ; Zhao, Yun ; Lu, Haojie ; Li, Hua ; Guo, Zhenyang ; Zhao, Shuang ; Wu, Bing

Partial endothelial-to-mesenchymal transition (EndMT) is an intermediate phenotype observed in endothelial cells (ECs) undergoing a transition toward a mesenchymal state to support neovascularization during (patho)physiological angiogenesis. Here, we investigated the occurrence of partial EndMT in ECs under hypoxic/ischemic conditions and identified general transcription factor IIH subunit 4 (GTF2H4) as a positive regulator of this process. In addition, we discovered that GTF2H4 collaborates with its target protein excision repair cross-complementation group 3 (ERCC3) to co-regulate partial EndMT. Furthermore, by using phosphorylation proteomics and site-directed mutagenesis, we demonstrated that GTF2H4 was involved in the phosphorylation of receptor coactivator 3 (NCOA3) at serine 1330, which promoted the interaction between NCOA3 and p65, resulting in the transcriptional activation of NF-κB and the NF-κB/Snail signaling axis during partial EndMT. In vivo experiments confirmed that GTF2H4 significantly promoted partial EndMT and angiogenesis after ischemic injury. Collectively, our findings reveal that targeting GTF2H4 is promising for tissue repair and offers potential opportunities for treating hypoxic/ischemic diseases.

2024-01-20·Journal of Clinical Oncology

A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.

作者: Ren, Ning ; Xu, Yongfeng ; Shi, Guoming ; Chen, Yi ; Fan, Jia ; Zhu, Xiaodong ; Zhou, Jian ; Wang, Xiaoying ; Shi, Yinghong ; Yi, Yong ; Ding, Zhenbin ; Lu, Pinxiang ; Gao, Qiang ; Ji, Yuan ; Qiu, Shuangjian ; Huang, Xiaoyong ; Liang, Fei ; Shen, Yinghao ; Li, Xiaowu ; Sun, Huichuan

488 Background: We have previously reported that GEMOX combined with lenvatinib and PD-1 antibody (GOLP regimen) showed promising efficacy as first-line treatment for advanced intrahepatic cholangiocarcinoma (iCCA), indicating that GOLP regimen may be an ideal conversion therapy for patients (pts) with potentially resectable advanced biliary tract cancer (BTC). This phase II trial explored the efficacy and safety of GOLP as conversion therapy in potentially resectable and locally advanced BTC. Methods: Patients with potentially resectable locally advanced BTC were enrolled and received tislelizumab (200mg, Q3W) and lenvatinib (8mg, QD) and GEMOX chemotherapy (Q3W) including gemcitabine 1000mg/m2 on day 1, 8 and oxaliplatin 85mg/m2 on day 1. Tumor responses were evaluated every 9 weeks according to RECIST v1.1, and the resectability was simultaneously discussed by MDT. For pts who were eligible for surgery, capecitabine alone was administered as adjuvant therapy after radical surgery. Pts who was not suitable for surgery continued to the original treatment regimen until progression or intolerable toxicity. The primary endpoint was R0 resection rate, and secondary endpoints included ORR, DCR, PFS, OS, CPR, MPR, RFS. Results: From December 2021 to July 2023, 41 pts were enrolled, 21 males and 20 females with a mean age of 57 years. 87.8% pts had iCCA, 7.3% had perihilar bile duct cancer and 4.9% had gallbladder cancer. TNM stage was II, IIIA, IIIB and IIIC for 2.4%, 34.1%, 58.5% and 4.9% of pts respectively. At cut-off date (September 10, 2023), the mean follow-up was 7.7 months, 39 pts completed at least three cycles of conversion therapy and 7 pts still administered with scheduled conversion therapy. The ORR was 43.9% (18/41) and the DCR was 87.8% (36/41). The median duration of therapy before surgery was 2.9 months (95%CI 2.6-4.6), R0 resection rate was 48.8% (20/41), and 2 pts underwent R1 resection. 9.1% (2/22) pts had a pCR and 22.7% (5/22) had an MPR. The most common grade 3/4 treatment-related adverse events (TRAEs) included neutropenia (31.7%), increased GGT (19.5%), leukopenia (12.2%). No grade 5 AEs occurred. Conclusions: This study demonstrates the high effectiveness and manageable safety of GOLP regimen as conversion therapy for potentially resectable locally advanced BTC. Survival data will continue to be followed up. Clinical trial information: NCT05156788 .

100 项与 Shanghai Xuhui District Central Hospital 相关的药物交易

登录后查看更多信息

100 项与 Shanghai Xuhui District Central Hospital 相关的转化医学

登录后查看更多信息